venBio Select Advisor
Latest statistics and disclosures from Avoro Capital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are UTHR, ASND, KRYS, MDGL, ARGX, and represent 52.57% of Avoro Capital Advisors's stock portfolio.
- Added to shares of these 10 stocks: ASND (+$1.4B), CYTK (+$142M), DFTX (+$103M), Hemab Therapeutics Holdings (+$71M), ARWR (+$53M), FTH (+$36M), QURE (+$35M), VRDN (+$18M), AVTX (+$17M), TSHA (+$15M).
- Started 3 new stock positions in Hemab Therapeutics Holdings, FTH, ASND.
- Reduced shares in these 10 stocks: Ascendis Pharma A S (-$1.2B), Apellis Pharmaceuticals (-$492M), Centessa Pharmaceuticals (-$454M), TERN (-$300M), UTHR (-$126M), Soleno Therapeutics (-$77M), , CELC (-$18M), RVMD (-$8.9M), VERA (-$7.1M).
- Sold out of its positions in Apellis Pharmaceuticals, Ascendis Pharma A S, Centessa Pharmaceuticals, MNKD, Soleno Therapeutics, TERN, ALKS.
- Avoro Capital Advisors was a net seller of stock by $-826M.
- Avoro Capital Advisors has $11B in assets under management (AUM), dropping by 10.85%.
- Central Index Key (CIK): 0001633313
Tip: Access up to 7 years of quarterly data
Positions held by venBio Select Advisor consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Avoro Capital Advisors
Avoro Capital Advisors holds 26 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| United Therapeutics Corp Common (UTHR) | 13.5 | $1.5B | -7% | 2.8M | 541.83 |
|
| Ascendis Pharma Ordinary Shares (ASND) | 12.2 | $1.4B | NEW | 5.1M | 266.72 |
|
| Krystal Biotech Common (KRYS) | 9.6 | $1.1B | 2.9M | 371.67 |
|
|
| Madrigal Pharmaceuticals Common (MDGL) | 8.8 | $984M | 1.8M | 536.95 |
|
|
| Argenx Se Sponsored ADR (ARGX) | 8.3 | $928M | 1.0M | 927.77 |
|
|
| Arrowhead Pharmaceuticals Common (ARWR) | 8.3 | $926M | +6% | 11M | 81.51 |
|
| Kymera Therapeutics Common (KYMR) | 7.7 | $857M | 7.5M | 114.67 |
|
|
| Revolution Medicines Common (RVMD) | 3.9 | $430M | -2% | 2.3M | 187.28 |
|
| Cytokinetics Common (CYTK) | 3.8 | $426M | +49% | 5.0M | 85.19 |
|
| Celcuity Common (CELC) | 3.2 | $356M | -4% | 3.4M | 104.62 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 3.2 | $352M | 6.6M | 53.67 |
|
|
| Xenon Pharmaceuticals Common (XENE) | 3.1 | $349M | 5.8M | 60.36 |
|
|
| Definium Therapeutics Common (DFTX) | 3.0 | $338M | +43% | 7.2M | 47.04 |
|
| Uniqure Nv Common (QURE) | 2.8 | $310M | +12% | 6.7M | 46.06 |
|
| Vera Therapeutics Common (VERA) | 2.2 | $246M | -2% | 5.7M | 42.91 |
|
| Taysha Gene Therapies Common (TSHA) | 1.5 | $163M | +10% | 24M | 6.81 |
|
| Ocular Therapeutix Common (OCUL) | 1.1 | $123M | 13M | 9.82 |
|
|
| Damora Therapeutics Common (DMRA) | 0.9 | $98M | 3.8M | 26.01 |
|
|
| Hemab Therapeutics Hldgs Common | 0.6 | $71M | NEW | 1.9M | 36.73 |
|
| Gh Research Ordinary Shares (GHRS) | 0.4 | $48M | 1.8M | 26.88 |
|
|
| Viridian Therapeutics Common (VRDN) | 0.4 | $46M | +66% | 2.5M | 18.37 |
|
| Septerna Common (SEPN) | 0.4 | $45M | 1.3M | 33.49 |
|
|
| Avalo Therapeutics Common (AVTX) | 0.4 | $43M | +65% | 2.3M | 18.48 |
|
| Faeth Therapeutics Common (FTH) | 0.3 | $36M | NEW | 1.4M | 25.00 |
|
| Whitehawk Therapeutics Common (WHWK) | 0.1 | $13M | 2.8M | 4.58 |
|
|
| Lexeo Therapeutics Common (LXEO) | 0.1 | $6.9M | -20% | 1.5M | 4.66 |
|
Past Filings by Avoro Capital Advisors
SEC 13F filings are viewable for Avoro Capital Advisors going back to 2014
- Avoro Capital Advisors 2026 Q2 filed Aug. 14, 2026
- Avoro Capital Advisors 2026 Q1 filed May 15, 2026
- Avoro Capital Advisors 2025 Q4 restated filed March 16, 2026
- Avoro Capital Advisors 2025 Q4 filed Feb. 17, 2026
- Avoro Capital Advisors 2025 Q3 filed Nov. 14, 2025
- Avoro Capital Advisors 2025 Q2 filed Aug. 14, 2025
- Avoro Capital Advisors 2025 Q1 filed May 15, 2025
- Avoro Capital Advisors 2024 Q4 filed Feb. 14, 2025
- Avoro Capital Advisors 2024 Q3 filed Nov. 14, 2024
- Avoro Capital Advisors 2024 Q2 filed Aug. 14, 2024
- Avoro Capital Advisors 2024 Q1 filed May 15, 2024
- Avoro Capital Advisors 2023 Q4 filed Feb. 14, 2024
- Avoro Capital Advisors 2023 Q3 filed Nov. 14, 2023
- Avoro Capital Advisors 2023 Q2 filed Aug. 14, 2023
- Avoro Capital Advisors 2023 Q1 filed May 15, 2023
- Avoro Capital Advisors 2022 Q4 filed Feb. 14, 2023